QVIDTVM Management LLC
In its 13F for Q4 2025 (holdings as of December 31, 2025, filed February 17, 2026), QVIDTVM Management LLC reported 13 stock positions worth $88.4 million. Its top holding was Bio-Rad Laboratories-A (BIO) at 28.6% of the portfolio, followed by Solventum (SOLV, 26.1%) and Amrize (AMRZ, 13.3%). Compared with Q3 2025, it opened 5 new positions, added to 2 and reduced 6. The biggest buy was a new position in Amrize (AMRZ) and the biggest sale Solventum (SOLV, shares −41%).
- Most Recent 13F
- Q2 2026
- Location
- THE WOODLANDS, TX
- CIK
- 0001912226
- Portfolio Value
- $88.4M (Q4 2025)
- SEC Filing
- 0001912226-26-000001 ↗ filed Feb 17, 2026
Holdings Value
Holdings 13 stocks · $88.4M
| BIO Bio-Rad Laboratories-A | 28.62% | 83,483 | $25.3M | Reduce -34.0% |
| SOLV Solventum Corp. | 26.06% | 290,615 | $23.0M | Reduce -41.5% |
| AMRZ Amrize Ltd. | 13.25% | 216,556 | $11.7M | New |
| XRAY Dentsply Sirona Inc. | 6.28% | 485,409 | $5.5M | Reduce -2.0% |
| ZGN Ermenegildo Zegna NV | 5.52% | 475,893 | $4.9M | Add +33892.4% |
| COTY Coty Inc. Class A | 5.28% | 1,515,888 | $4.7M | Reduce -5.9% |
| BRC INC-A | 4.27% | 3,400,681 | $3.8M | Add +1.8% |
| EQIX Equinix Inc. | 3.84% | 4,426 | $3.4M | New |
| NBIS Nebius Group NV | 3.29% | 34,700 | $2.9M | New |
| ARE Alexandria Real Estate Equit | 2.21% | 40,000 | $2.0M | New |
| WAB Wabtec Corp. | 0.82% | 3,404 | $727K | Reduce -64.6% |
| LAB Standard Biotools Inc. | 0.33% | 229,338 | $294K | New |
| RTO Rentokil Initial PLC-SP ADR | 0.23% | 6,879 | $203K | Reduce -99.6% |
Portfolio Sells Q3 2025 → Q4 2025
| SOLV Solventum Corp. | Reduce -41.5% | 26.06% | −12.97 |
| BIO Bio-Rad Laboratories-A | Reduce -34.0% | 28.62% | −9.55 |
| COTY Coty Inc. Class A | Reduce -5.9% | 5.28% | −1.72 |
| WAB Wabtec Corp. | Reduce -64.6% | 0.82% | −1.25 |
| XRAY Dentsply Sirona Inc. | Reduce -2.0% | 6.28% | −0.49 |
| RTO Rentokil Initial PLC-SP ADR | Reduce -99.6% | 0.23% | +0.05 |
Portfolio Buys Q3 2025 → Q4 2025
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 14 | $76.6M | BIO, NBIS, AMRZ, ORCL, SOLV |
| Q1 2026 | 14 | $81.4M | BIO, SOLV, AMRZ, NBIS, ORCL |
| Q4 2025 | 13 | $88.4M | BIO, SOLV, AMRZ, XRAY, ZGN |
| Q3 2025 | 8 | $92.9M | SOLV, BIO, COTY, XRAY, BRC INC-A |
| Q2 2025 | 8 | $99.8M | SOLV, BIO, COTY, XRAY, RTO |
| Q1 2025 | 8 | $113.1M | SOLV, BIO, RTO, COTY, XRAY |
| Q4 2024 | 8 | $124.2M | BIO, SOLV, RTO, BRC INC-A, XRAY |
| Q3 2024 | 8 | $142.9M | BIO, SOLV, WAB, RTO, XRAY |
| Q2 2024 | 7 | $125.0M | BIO, RTO, SOLV, WAB, BRC INC-A |
| Q1 2024 | 10 | $124.2M | BIO, RTO, WAB, BRC INC-A, XRAY |